

*Q<sup>2</sup>*

A<sup>1</sup> represents a substituted or unsubstituted, single ring aromatic heterocyclyl group having 4 to 7 ring atoms and comprising up to 4 hetero atoms in each ring selected from oxygen, sulphur or nitrogen, the substituents for the heterocyclyl group being up to 4 substituents for the heterocyclyl group being up to 4 substituents selected from the group consisting of:

C<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkoxy, aryl and halogen or any two substituents on adjacent carbon atoms, together with the carbon atoms to which they are attached, may form an aryl group, and wherein the carbon atoms of the aryl group represented by the said two substituents may themselves be substituted or unsubstituted;

R<sup>1</sup> represents a hydrogen atom, a C<sub>1-12</sub>-alkyl group, a C<sub>1-12</sub>-alkyl group, a C<sub>1-6</sub> alkylcarbonyl group, an aryl-C<sub>1-12</sub>-alkyl group the aryl moiety being substituted or unsubstituted, or a substituted or unsubstituted aryl group;

any aryl group being phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C<sub>1-12</sub>-alkyl, phenyl, C<sub>1-12</sub>-alkoxy, halo-C<sub>1-12</sub>-alkyl, hydroxy, amino, nitro, carboxy, C<sub>1-12</sub>-alkoxycarbonyl, C<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkylcarbonyloxy, or C<sub>1-12</sub>-alkylcarbonyl group;

R<sup>2</sup> and R<sup>3</sup> each represent hydrogen, or R<sup>2</sup> and R<sup>3</sup> together represent a bond;

62  
A<sup>2</sup> represents a benzene ring having three optional substituents which may be selected from halogen, substituted or unsubstituted alkyl or alkoxy; substituents for the alkyl group being selected from the groups consisting of halogen, C<sub>1-12</sub>-alkyl, phenyl, C<sub>1-12</sub>-alkyl, phenyl, C<sub>1-12</sub>-alkoxy, halo-C<sub>1-12</sub>-alkyl, hydroxy, amino, nitro, carboxy, C<sub>1-12</sub>-alkoxycarbonyl, C<sub>1-12</sub>-alkoxycarbonyl-C<sub>1-12</sub>-alkyl, C<sub>1-12</sub>-alkylcarbonyloxy, or C<sub>1-12</sub>-alkylcarbonyl; and

n represents an integer in the range of from 2 to 6.--

Claims 2 and 3, line 1, change "claim 1" to -- claim 52

-- .  
Claims 7 and 9, line 1, change "claim 1" to -- claim 52

-- .  
Claims 10-48, line 1, change "claim 1" to -- claim 52

-- .  
Amend claim 49 as follows:

63  
~~52~~<sup>52</sup>. (Amended) A pharmaceutical composition comprising a non-toxic effective amount of the [a] compound of formula (I) according to claim ~~52~~<sup>1</sup> [1], or a tautomeric form thereof or a pharmaceutically acceptable salt thereof or pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.

Claims 50 and 51, line 4, change "claim 1" to -- claim 52 -- .

Add the following additional claims:

64  
~~49-53~~<sup>49</sup>. A compound according to claim ~~52~~<sup>1</sup>, wherein A<sup>1</sup> represents a substituted or unsubstituted single ring aromatic heterocyclyl group having 5 or 6 ring atoms.

50  
--~~54~~. A compound according to claim ~~52~~<sup>1</sup>, wherein A<sup>1</sup> represents a substituted or unsubstituted thiazolyl, oxazolyl, pyridyl or pyrimidinyl group.

51  
--~~55~~. A compound according to claim ~~52~~<sup>1</sup>, wherein A<sup>1</sup> represents a substituted or unsubstituted oxazolyl, pyridyl or pyrimidinyl group.

ay  
sub 56. A method for the treatment and/or prophylaxis of diseases selected from the group consisting of hyperglycaemia, hyperlipidaemia, hypertension, cardiovascular diseases and eating disorders in a human or a non-human mammal which comprises administering to said human or non-human mammal in need thereof, an effective, non-toxic, amount of a compound of formula (I) according to claim 52, or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically acceptable solvate thereof.--

#### Extra Claim Fees

The replacement of claim 1 by new claim 52 does not require an extra claim fee.

New dependent claims 53-56 totaling four (4) in number require a fee of 4 x \$12.00 or \$48.00.

A check in that amount is enclosed. If there are any additional charges, please apply the cost to Account No. 08-2776.

#### R E M A R K S

Claims 2-56 are in the case.

The present application was prematurely finally rejected in the First Office Action on the ground that it is a continuation of applicant's earlier application Serial No. 238,764. Actually,